GeneDx Holdings Corp.
GeneDx Holdings Corp. (WGS) Revenue
Annual & quarterly revenue history · segment & region breakdown
WGS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGeneDx Holdings Corp. trailing twelve-month (TTM) revenue is $0.44B, an increase of 39.97% year-over-year from $0.43B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.43B | +$0.12B | +39.97% |
| 2024-12-31 | $0.31B | +$0.10B | +50.79% |
| 2023-12-31 | $0.20B | -$0.03B | -13.69% |
| 2022-12-31 | $0.23B | +$0.02B | +10.60% |
| 2021-12-31 | $0.21B | +$0.03B | +18.33% |
| 2020-12-31 | $0.18B | -$0.02B | -8.59% |
| 2019-12-31 | $0.20B | — | — |
Compare revenue vs peers
Medical - Healthcare Information ServicesCompare WGS revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income GeneDx Holdings Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
GeneDx Holdings Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from GeneDx Holdings Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
WGS revenue · 4 questionsWGS's trailing twelve-month (TTM) revenue is $0.44B. That is an increase of 39.97% year-over-year from $0.43B in FY2025.
▸ Source: FMP · GeneDx Holdings Corp. SEC filings · GAAP · GeneDx Holdings Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026